Randox Biosciences and Metabolic Syndrome
Randox Biosciences and Metabolic Syndrome
The Evidence Evolution is a fully automated immune-analyser with random access. The machine has the capability to process up to 2640 tests per hour with up to 44 analytes screened per biochip. With a wide range test menu Randox can offer the market the service they expect with state-of-the-art intuitive touchscreen software and advanced precision bio-drive robotics.
Metabolic syndrome is described as a combination of diabetes, high blood pressure and obesity. As result of three health conditions going on, it puts the individual at greater risk of developing coronary heart disease, stroke and many other risks. 1 As well as developing additional health conditions it can cause damage to the blood vessels, the blood pressure damages the blood vessels, the obesity causes a lot of strain on the blood vessels and the heart.2 Therefore, can result in serious long-term risks.
Metabolic disease is very common. Studies state that the serious health condition affects about 23% of adults. 3One in four adults in the UK are currently living with metabolic syndrome and often becomes more common with age2.
Usually it affects those who are overweight or considered obese, have an unbalanced diet containing high levels of sugar and fat and have high cholesterol and extremely high blood pressure2 therefore, the condition can be prevented by reducing the risks.
1 According to the NHS, metabolic syndrome occurs when a person has three or more of the following measurements:
- Abdominal obesity (Waist circumference of greater than 40 inches in men, and greater than 35 inches in women)
- Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater
- HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women
- Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater
- Fasting glucose of 100 mg/dL or greater
There are many ways to prevent metabolic syndrome from developing, making lifestyle changes for example, ensuring their weight is healthy by increasing physical exercise, eating a well-balanced healthy diet containing whole grains, fruit, vegetables and fish and finally, visiting the GP to monitor and manage blood glucose, blood cholesterol and blood pressure, quit smoking and managing your stress.
Randox offers the Evidence Evolution including two Metabolic Syndrome Arrays which allows multiplex testing from a single sample allowing rapid turnaround time and are suitable for both serum and plasma samples.
Metabolic Syndrome Array I
- Ferritin
- Interleukin-6 (IL-6)
- Insulin
- Leptin
- Plasminogen Activator Inhibitor-1 (PAI-1)
- Resistin
- Tumour Necrosis Factor α (TNFα)
Metabolic Syndrome Array II
- Adiponectin
- C-reactive Protein (CRP)
- Cystatin C
For more information on our Evidence Series or Metabolic Syndrome Range of Assays, contact us at EvidenceSeries@randox.com
The Evidence Series
Having developed the patented Biochip Array Technology following £250 million investment in research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series.
The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.
Have a read below of the overview of each analyser in the Evidence Series
Evidence Evolution
The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.
Evidence
As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.
Evidence Investigator
The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.
Evidence MultiSTAT
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on any of the Evidence Series analysers, please visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
The Evidence Evolution – The newest member of the Evidence series
Launched in 2016, the Evidence Evolution has set new standards in the world of clinical, forensic and food testing.
With the most extensive test menu on offer, we can provide more tests than any other supplier and we are continually investing in R&D to keep up with industry developments and challenges, such as our extensive clinical test menu with a range of routine and novel tests including our CKD panel which detects the early stages of Chronic Kidney Disease.
The Evidence Evolution utilises Randox’s cutting-edge Biochip Array Technology, offering diagnostic testing from a single sample. The Evidence Evolution boasts 2640 tests per hour and when put to the test against our competitor machines, the Evidence Evolution gives a true walk away time of up to 2 hours, meaning staff can fully load the machine and get up to 44 results from each sample every minute, while they get on with important laboratory tasks.
The Evidence Evolution has been designed to meet the needs of a variety of laboratories. Delivering quality results, efficiently and economically in forensic and clinical immunoassay locations.
The Evidence Evolution is the latest development in our Evidence Series range, which was first launched in 2002. This trusted technology is powered by Biochip and is used throughout the world in a range of different sites for clinical, toxicology and food testing. The Evidence Series has a range of analysers that can meet the need of any laboratory.
For more information on any of the Evidence Series analysers, please visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
The Evidence Series: What is it and how is it changing the diagnostic landscape forever?
Having developed the patented Biochip Array Technology following £250 million investment in diagnostic research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series.
The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.
Have a read below of the overview of each analyser in the Evidence Series
Evidence Evolution
The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.
Evidence
As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.
Evidence Investigator
The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.
Evidence MultiSTAT
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on any of the Evidence Series analysers, please visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Biochip Carrier Applications in the Randox Evidence Series
Biochip Array Technology is the fundamental component which drives the Randox Evidence Series immunoanalysers. The simultaneous detection of multiple analytes from a single sample allows for a complete patient profile, providing exceptional time, resource and cost savings.
The Evidence Series analysers all carry the Biochip in different applications. In order to gain a better understanding of how it is utilised, the illustrations below demonstrate how adaptable and flexible the technology is across the Evidence Series.
Evidence Evolution
- One strip contains 10 biochips
- Analyser can hold 20 strips
- Can produce a throughput of up to 2640 tests per hour
Evidence
- Each cassette contains 10 carriers
- Each carrier has 9 wells
- Analyser can hold 4 cassettes at once
- Can produce a throughput of up to 3960 tests per hour
Evidence Investigator
- Analyser holds 1 cartridge
- 1 cartridge contains 9 wells
- Thermoshaker capable of carrying 6 cartridges
- Can produce a throughput of up to 2376 tests per hour
Evidence MultiSTAT
- Analyser holds 1 cartridge
- Cartridge comes pre-loaded with reagents and QC
- Can produce a throughput of up to 132 tests per hour
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on any of the Evidence Series analysers, visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
The Evidence Evolution: The world’s most advanced immunoassay analyser
What sets the Evidence Series apart from its competitors is its flexibility across the range of immunoassay analysers. No other range of analysers has the capability in terms of throughput in comparison to the Evidence Series. With this established, we are delighted to introduce the latest in the Evidence Series range, the Evidence Evolution.
Join the Evolution
We believe that the Evidence Evolution is the world’s most advanced immunoassay analyser. The Evidence Evolution is the most versatile analyser Randox has ever produced. By utilising the same multiplex technology as the other Evidence Series analysers, the Evidence Evolution can process up to 44 results from a single sample, with a maximum throughput of up to 2640 tests per hour. With such a high volume of potential throughput, you may think that reporting time will be compromised, that is simply not the case. The Evidence Evolution can produce the first set of results in less than 36 minutes, with one sample of up to 44 results reported every minute after. The speed of reporting time distinguishes the Evidence Evolution from its competitors, and allows the analyser to further display its capabilities.
Innovation
By utilising patented Biochip Array Technology, the Evidence Evolution offers batch analysis, true random access and STAT testing capabilities. These, combined with retrospective testing, allows the user to build a more in-depth patient profile.
With such swift reporting times, the Evidence Evolution can boast of a true walkaway time of 2 hours, in a laboratory setting, this can be vital. With multiple daily tasks to be completed, time is of the essence, and the Evidence Evolution has been designed to lessen the workload of laboratory staff. By being able to offer a combination of continuous sample and reagent loading, plus automated on-board sample dilution, the Evidence Evolution will have a positive impact in busy laboratories.
Complete Picture
A fast reporting time and high throughput capabilities is just the tip of what the Evidence Evolution can offer. The analyser has the capability to test across multiple matrices, allowing for more flexibility in sampling. It also comes equipped with state of the art intuitive software and advanced precision bio-drive robotics, meaning the Evidence Evolution is an analyser that has been designed and developed to meet the needs of a modern, high throughput laboratory, by a company that has a deep understanding of laboratory needs.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on the Evidence Evolution, or any of the Evidence Series analysers, please visit http://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Welcome to the Evidence Series
Introduction
For over 30 years, we have been researching and manufacturing market-leading diagnostics products globally. With a mission statement of ‘dedicated to improving health worldwide’ the patient needs are a central focus of everything we do. It is this experience and commitment to improving healthcare that has allowed us to continually improve our product offering and make advancements globally to reach as many people as possible and provide greater diagnostic facilities.
From this experience and commitment to research, we believe we have developed a technology that has changed diagnostic testing forever.
Biochip Array Technology
In 2002, we invented a world first, which changed the landscape of diagnostic testing forever. Biochip Array Technology is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
Biochip Array Technology uniquely offers immunoassay diagnostic testing for simultaneous multi-analyte biomarker detection. After addition of a single patient sample to the biochip, analytes present in the sample bind to the specific biochip bound ligands. The degree of binding is determined using a chemiluminescent light source and quantified using a Charge Coupled Device (CCD) camera and imaging system.
An individual biochip has up to 49 Discrete Test Regions with each detecting a different biomarker. That means up to 44 tests can be carried out simultaneously, with the additional DTRs being reserved for visual quality control and visual reference; a feature unique to Biochip Array Technology.
The Evidence Series
Having developed this patented technology following £250 million investment in research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series. The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.
Have a read below of the brief overview of each analyser in the Evidence Series
Evidence Evolution
The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.
Evidence
As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.
Evidence Investigator
The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.
Evidence MultiSTAT
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities. For more information on any of the Evidence Series analysers, please visit http://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Evidence Series Immunoanalysers
Powered by Biochip Array Technology
In 2002, Randox invented a world first, Biochip Array Technology (BAT), instantly changing the landscape of diagnostic testing forever. BAT is a multi-analyte platform which provides an unrivaled increase in patient information per sample. Instead of a patient sample needing to be subdivided for each test result, or in some cases re-collected, Biochip Array Technology offers a diagnostic patient profile with each patient sample. So now the patient’s needs become the focus, as BAT delivers the multiple results needed for improved diagnosis.
With over £250 million invested into Biochip Array Technology research and development, Randox have launched a range of Biochip Array Technology immunoanalysers – The Evidence Series. This includes the Evidence, the Evidence Investigator and the Evidence MultiSTAT. Each analyser is developed with boundary pushing engineering, designed to make financial, labour and time savings for the end user. Utilising this technology, the Evidence series guarantees cost-effective, highly accurate and flexible testing solutions.
Click on the immunoanalysers below for more information
Evidence Investigator
Evidence MultiSTAT
Evidence
Why choose the Evidence Series?
Biochip Array Technology Test Menu
Adhesion Molecules
| E-Selectin | P-Selectin | L-Selectin | |
| Intercellular Adhesion Molecule-I – ICAM-I | Vascular Cell Adhesion Molecule-I –VCAM-I | ||
Alzheimer’s
| Apolipoprotein E4 –ApoE4 | Pan Apolipoprotein E – Apo E |
Anaemia
| Ferritin | Folate | Vitamin B12 |
Bone Disease
| Vitamin D | |||
Cancer
| Carcinoembryonic Antigen – CEA | Free Prostate Specific Antigen − FPSA | Total Prostate Specific Antigen − TPSA | |
Cardiac
| Cardiac Troponin I – cTnl | Creatine Kinase MB – CKMB | Heart Fatty Acid Binding Protein – H-FABP | Myoglobin |
Cerebral
| Brain-Derived Neurotrophic Factor − BDNF | Neuron Specific Enolase − NSE | ||
Cytokines
| Epidermal Growth Factor − EGF | Granulocyte Macrophage Colony Stimulating Factor | Interferon-γ − IFN-γ | Interleukin-1 alpha − IL-1α |
| Interleukin-1 beta − IL-1β | Interleukin-2 − IL-2 | Interleukin-3 − IL-3 | Interleukin-4 − IL-4 |
| Interleukin-5 − IL 5 | Interleukin-6 − IL-6 | Interleukin-7 − IL-7 | Interleukin-8 − IL-8 |
| Interleukin-4 − IL-4 | Interleukin-5 − IL 5 | Interleukin-6 − IL-6 | Interleukin-7 − IL-7 |
| Interleukin-8 − IL-8 | Interleukin-10 − IL-10 | Interleukin-12p70 − IL-12p70 | Interleukin-13 − IL-13 |
| Interleukin-15 − IL 15 | Interleukin-23 − IL-23 | Macrophage Infl ammatory Protein-1α − MIP-1α | Matrix Metalloproteinase 9 − MMP 9 |
| Monocyte Chemotactic Protein-1 − MCP-1 | Soluble IL-2 Receptor Alpha − sIL-2Rα | Soluble IL-6 Receptor − sIL-6R | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 |
| Soluble Tumour Necrosis Factor Receptor 2 − sTNFR2 | Tumour Necrosis Factor-α − TNF-α | Vascular Endothelial Growth Factor − VEGF | |
Diabetes
| Insulin | |||
Endocrine
| Cortisol | Dehydroepiandrosterone-Sulphate- DHEAS | ||
Fertility / Pregnancy
| Estradiol | Follicle Stimulating Hormone − FSH | Luteinizing Hormone − LH | Progesterone |
| Prolactin | Sex Hormone Binding Globulin − SHBG | Testosterone | |
Fibrinolysis
| D-Dimer |
Gastro
| Gastrin 17 – GI7 | Helicobacter pylori – H. pylori | Pepsinogen I – PGI | Pepsinogen II – PGII |
Metabolic
| Adiponectin | Ferritin | Insulin | Leptin |
| Plasminogen Activator Inhibitor − PAI-1 | Resistin |
Renal
| Adiponectin | Complement C3a des Arginine – C3a des Arg | CRP (C-Reactive Protein) | Cystatin C |
| D-Dimer | Epidermal Growth Factor − EGF | Fatty Acid Binding Protein-1 − FABP1 | Interleukin-8 − IL-8 |
| Macrophage Infl ammatory Protein-1α − MIP-1α | Neutrophil Gelatinase – Associated Lipocalin – NGAL | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 | Soluble Tumour Necrosis Factor Receptor 2 − sTNFR2 |
Stroke
| Brain-Derived Neurotrophic Factor − BDNF | D-Dimer | Glial Fibrillary Acidic Protein − GFAP | Glutathione S – Transferase Pi – GSTPi |
| Heart Fatty Acid Binding Protein – H-FABP | Interleukin-6 − IL-6 | Nucleoside Diphosphate Kinase – NDKA | Neuron Specifi c Enolase − NSE |
| Parkinson Protein 7 − PARK-7 | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 | ||
Thyroid
| Anti-Thyroglobulin − Anti-Tg | Anti-Thyroid Peroxidase − Anti-TPO | Free Tri-iodothyronine − FT3 | Free Thyroxine − FT4 |
| Thyroid Stimulating Hormone − TSH | Thyroxine Binding Globulin − TBG | Total Tri-iodothyronine − TT3 | Total Thyroxine − TT4 |
Toxicology
| Amphetamine | Barbiturates | Benzodiazepines I | Benzodiazepines II |
| Buprenorphine | Cannabinoids – THC | Cocaine Metabolite | Dextromethorphan |
| Fentanyl | Ketamine | Meprobamate | Methadone |
| Opiate | Oxycodone I | Oxycodone II | Phencyclidine – PCP |
| Tramadol | Tricyclic Antidepressants | Zolpidem | |
Molecular
| 20 SNPs | Adenovirus A/B/C/D/E | APOB – 1 mutation | Bordetella pertussis |
| BRAF – 1 mutation | Chlamydia trachomatis – (CT) | Chlamydophila pneumoniae | Coronavirus 229E/NL63 |
| Coronavirus OC43/HKU1 | Enterovirus A/B/C | Haemophilus ducreyi – (HD) | Haemophilus influenzae |
| Herpes simplex Virus 1– (HSV-1) | Herpes simplex Virus 2 – (HSV-2) | Human Bocavirus 1/2/3 | Human Metapneumovirus – hMPV |
| Influenza A/B | KRAS – 16 mutations | LDLR – 38 mutations | Legionella pneumophila |
| Moraxella catarrhalis | Mycoplasma genitalium – (MG) | Mycoplasma hominis – (MH) | Mycoplasma pneumoniae |
| Neisseria gonorrhoea – (NG) | Parainfluenza Virus 1/2/3/4 | PCSK9 – 1 mutation | PIK3CA – 3 mutations |
| Respiratory Syncytial Virus a – RSVa | Respiratory Syncytial Virus b – RSVb | Rhinovirus A/B | Streptococcus pneumoniae |
| Treponema pallidum – (TP) | Trichomonas vaginalis – (TV) | Ureaplasma urealyticum – (UU) | |
Veterinary Residues / Food Diagnostics
| 17β-Clostebol | 5-hydroxy Flunixin | Aflatoxin B1 | Aflatoxin G1/G2 |
| Aflatoxin M1 | AHD | Amikacin/Kanamycin | Amino Benzimidazoles |
| Amoxicillin | AMOZ | Amphenicols | Ampicillin |
| AOZ | Apramycin | Avermectins | Bacitracin |
| Baquiloprim | Benzimidazoles | Beta-agonists | Beta-Lactams |
| Boldenone | Cefapirin | Cefoperazone | Cefquinome |
| Ceftiofur | Cefuroxime | Cephalexin | Cephalonium |
| Chloramphenicol | Chlormadinone | Clopidol | Cloxacillin |
| Corticosteroids | Dapsone | Decoquinate | Deoxynivalenol |
| Dexamethasone | Diacetoxyscirpenol | Diclazuril | Dicloxacillin |
| Dihydrostreptomycin | Ergot Alkaloids | Erythromycin | Ethinylestradiol |
| Fumonisins | Gentamicin | Gestagens | Halofugine |
| Hygromycin B | Imidocarb | Kanamycin | Lasalocid |
| Levamisole | Lincomycin | Lincosamides | MaduramicinG |
| Melamine | Meloxicam | Metamizole | Methyltestosterone |
| Monensin | Moxidectin (MXD) | Nandrolone | Neomycin/Paromomycin |
| Nicarbazin | Nitroimidazoles | Nitroxynil | Novobiocin |
| Ochratoxin A | Oxacillin | Paxilline | Penicillin G |
| Penicillin V | Phenylbutazone | Pirlimycin | Polymixins |
| Quinolones | Ractopamine | Rifaximin | Robenidine |
| Salinomycin | SEM | Spectinomycin | Spiramycin |
| Spiramycin/Josamycin | Stanozolol | Stilbenes | Streptomycin |
| Sulfaguanidine | Sulfamethazine | Sulphachlorpyridazine | Sulphadiazine |
| Sulphadimethoxine | Sulphadoxine | Sulphamerazine | Sulphamethazine |
| Sulphamethizole | Sulphamethoxazole | Sulphamethoxypyridazine | Sulphapyridine |
| Sulphaquinoxaline | Sulphathiazole | Sulphisoxazole | Sulphonamides |
| T2 toxin | Tetracyclines | Thiabendazole | Thiamphenicol |
| Tobramycin | Tolfenamic Acid | Toltrazuril | Trenbolone |
| Triclabendazole | Trimethoprim | Tylosin | Tylosin B/Tilmicosin |
| Virginiamycin | Virginiamycin M1 | Zearalenone | Zeranol |
